Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
Piper Sandler analyst Kashy Harrison maintains Codexis (NASDAQ:CDXS) with a Overweight and lowers the price target from $9 to $8.
Stocks · News reference
Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform
The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Codexis Affirms FY2026 Sales Guidance of $72.000M-$76.000M vs $74.099M Est
Codexis (NASDAQ:CDXS) affirms FY2026 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.099 million estimate.
Codexis Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $14.915M Beat $14.348M Estimate
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the same